North America’s BEST Small Cap Stock Ideas
Verisante Technology (VRS – $0.15), a medical device company committed to commercializing innovative systems for the early detection of cancer, started the application process with the Food and Drug Administration (FDA) to market and sell the Aura, a device for the detection of skin cancer, in the United States. Aura is a non-invasive Raman spectroscopy system designed to aid medical […]
Read more
This week we have updates on LiqTech International (LIQT) and Verisante Technology (VRS). LiqTech International (LIQT – $2.05), the Danish clean technology company that manufactures state-of-the-art filtration products announced first quarter results for the period ending March 31, 2014. Net sales for the quarter ending March 31, 2014 were $3,197,502 compared to $3,399,148 for the comparable period in 2013, representing […]
Read moreThis week we have updates on the medical device company Verisante Technology (VRS) and on the Indianapolis based franchisor and licensor of pizzas and subs Noble Roman’s (NROM). The Chinese Patent Office granted Verisante Technology (VRS – $0.20) a patent which allows the Company to use its Core devices for endoscopic applications in cancer detection. Furthermore, this patent enhances Verisante’s […]
Read moreVerisante Technology (VRS – $0.58) entered into an exclusive agreement with BO-Pharma BV to distribute, service and support technical training of the Aura in Belgium, the Netherlands and Luxemburg, the so-called Benelux countries. In the Benelux region, BO-Pharma is the largest independent distributor of medical devices for skin care treatments and other devices for use in dermatological practices. After Clarion […]
Read moreVerisante Technology, Inc. (VRS – $0.53) is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura is used for skin cancer detection, while the Verisante Core, which is still in development, is applicable for lung, colon and cervical cancer detection. Skin cancer is the most common form of cancer and is […]
Read moreMr. Braun, the President and CEO of Verisante Technology (VRS – $0.54) spoke at the Canadian Association of Medical Radiation Technologists’ (CAMRT) Annual General Conference a few days ago. The conference was a success as about 1,500 technologists attended. Mr. Braun presented during the Canadian Innovation Showcase, a session that highlights Canadian companies who are breaking new ground with revolutionary […]
Read moreThe first beta units of Verisante’s (VRS – $0.55) Aura are finished and ready to undergo safety tests. Once these tests are completed the devices will be placed in several clinics for actual field testing. During these field tests, a doctor will first scan a patient’s skin lesions with the Aura. When the doctor finds a suspicious lesion, it will […]
Read moreVerisante Technology, Inc. (VRS – $0.56) is a medical device company committed to commercializing innovative systems for the detection of cancer. The Verisante Aura is used for skin cancer detection and the Verisante Core for lung, colon and cervical cancer detection. Skin cancer is currently diagnosed based on visual examination by a dermatologist or general practitioner, leading to unnecessary biopsies […]
Read moreStudy data collected from tests on 1,000 skin lesions shows higher success rate than competitors’ devices. We’re pleased to announce the release of another Smallcaps.us interview, this time taking a closer look at an up and coming company in the medical devices domain. Verisante Technology Inc. (VRS – $0.63) develops cancer detection devices and has been generating buzz among investors […]
Read more